作者
Harald Mischak, John PA Ioannidis, Angel Argiles, Teresa K Attwood, Erik Bongcam‐Rudloff, Mark Broenstrup, Aristidis Charonis, George P Chrousos, Christian Delles, Anna Dominiczak, Tomasz Dylag, Jochen Ehrich, Jesus Egido, Peter Findeisen, Joachim Jankowski, Robert W Johnson, Bruce A Julien, Tim Lankisch, Hing Y Leung, David Maahs, Fulvio Magni, Michael P Manns, Efthymios Manolis, Gert Mayer, Gerjan Navis, Jan Novak, Alberto Ortiz, Frederik Persson, Karlheinz Peter, Hans H Riese, Peter Rossing, Naveed Sattar, Goce Spasovski, Visith Thongboonkerd, Raymond Vanholder, Joost P Schanstra, Antonia Vlahou
发表日期
2012/9
期刊
European journal of clinical investigation
卷号
42
期号
9
页码范围
1027-1036
出版商
Blackwell Publishing Ltd
简介
Eur J Clin Invest 2012; 42 (9): 1027–1036
Abstract
While large numbers of proteomic biomarkers have been described, they are generally not implemented in medical practice. We have investigated the reasons for this shortcoming, focusing on hurdles downstream of biomarker verification, and describe major obstacles and possible solutions to ease valid biomarker implementation. Some of the problems lie in suboptimal biomarker discovery and validation, especially lack of validated platforms with well‐described performance characteristics to support biomarker qualification. These issues have been acknowledged and are being addressed, raising the hope that valid biomarkers may start accumulating in the foreseeable future. However, successful biomarker discovery and qualification alone does not suffice for successful implementation. Additional challenges include, among others, limited access to …
学术搜索中的文章
H Mischak, JPA Ioannidis, A Argiles, TK Attwood… - European journal of clinical investigation, 2012